Key result
Acute STEMI linked to a ~13-fold increase in monocytic miR-143 expression versus healthy controls.
Why the study?
Are specific microRNAs in circulating monocytes differentially expressed in patients with acute STEMI compared to healthy donors?
Case-Control (n=44)
No
Are specific microRNAs in circulating monocytes differentially expressed in patients with acute STEMI compared to healthy donors?
Effect estimate: 12.7 fold change
p-value: p=0.001
Specific microRNAs in circulating monocytes, such as miR-143, are differentially expressed in the early phase of STEMI and may serve as novel cellular biomarkers.
Monocyte miR profiling identifies candidate STEMI biomarkers; leaves open diagnostic utility pending larger validation studies.
MicroRNA has been increasingly suggested to be involved in vascular inflammation. The aim of this study was to assess the expression profile of miRs as possible novel cellular biomarkers in circulating monocytes in patients with ST-segment elevation myocardial infarction (STEMI). Microarray techniques and TaqMan polymerase chain reaction were used to analyse the global expression of 352 miRNAs in peripheral blood monocytes from healthy donors (n = 20) and patients (n = 24) with acute STEMI. The expression level of miR-143 in monocytes from STEMI patients compared to healthy controls was increased, whereas the expression of miR-1, -92a, -99a, and -223 was reduced significantly. During 3.5 ± 1.5 months of follow-up miR-1 and -223 were back to baseline, whereas miR-92a and -99a return to normal levels over 3 months, but remained lower than healthy controls. Furthermore, monocytic expression of miR-143 was positively correlated with hs-CRP (R2 = 0.338; P < 0.031), but not with cTnT. Importantly, treatment of monocytes isolated from healthy individuals with INFγ, but not LPS or TNFα caused an upregulation of miR-143 and downregulation of miR-1. Our findings identify circulating monocytes as putative biomarkers and as novel carriers for the cell-specific transfer of miRs in the early phase of myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Parahuleva et al. (2017) conducted a case-control in ST-segment elevation myocardial infarction (STEMI) (n=44). Acute ST-segment elevation myocardial infarction (STEMI) vs. Healthy controls was evaluated on Expression level of miR-143 in peripheral blood monocytes (12.7 fold change, p=0.001). Acute STEMI was associated with a 12.7-fold increase in monocytic miR-143 expression and significant reductions in miR-1, -92a, -99a, and -223 compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: